TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer

To evaluate the optimal treatment conditions and effects of TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy in patients with localised prostate cancer. To evaluate the safety and quality of life after TOOKAD® Soluble VTP treatment in patients with localised prostate cancer.

[1]  Zheng Huang,et al.  Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer , 2005, Lasers in surgery and medicine.

[2]  A. Evans,et al.  Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. , 2007, The Journal of urology.

[3]  Avigdor Scherz,et al.  WST11, A Novel Water-soluble Bacteriochlorophyll Derivative; Cellular Uptake, Pharmacokinetics, Biodistribution and Vascular-targeted Photodynamic Activity Using Melanoma Tumors as a Model¶ , 2005, Photochemistry and Photobiology.

[4]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[5]  G. Santoni,et al.  Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder , 2012, Advances in urology.

[6]  D. Wood,et al.  Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? , 2009, Current opinion in urology.

[7]  H. Mimata,et al.  Focal Therapy in the Management of Prostate Cancer: An Emerging Approach for Localized Prostate Cancer , 2012, Advances in urology.

[8]  A. Scherz,et al.  Novel Water‐soluble Bacteriochlorophyll Derivatives for Vascular‐targeted Photodynamic Therapy: Synthesis, Solubility, Phototoxicity and the Effect of Serum Proteins ¶ , 2005, Photochemistry and photobiology.

[9]  G. Lu-Yao.  Re: Radical Prostatectomy Versus Observation for Localized Prostate Cancer Wilt TJ, Brawer MK, Jones KM, et al., Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group , 2013 .

[10]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[11]  H. Ahmed,et al.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study , 2012, The Lancet. Oncology.

[12]  Avigdor Scherz,et al.  Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. , 2009, The journal of physical chemistry. A.

[13]  L. Klotz.  Active Surveillance for Prostate Cancer: A Review , 2010, Current urology reports.

[14]  Nacim Betrouni,et al.  A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11 , 2011, Physics in medicine and biology.

[15]  L. Klotz,et al.  How much does Gleason grade of follow‐up biopsy differ from that of initial biopsy in untreated, Gleason score 4–7, clinically localized prostate cancer? , 2007, The Prostate.

[16]  L. Klotz,et al.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. , 2010, The Journal of urology.

[17]  A. Evans,et al.  Vascular‐targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses , 2008, BJU international.

[18]  Avigdor Scherz,et al.  Photodynamic therapy with Pd‐bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts , 2003, International journal of cancer.

[19]  Z. Hall.  Cancer , 1906, The Hospital.

[20]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[21]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[22]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Vyacheslav Kalchenko,et al.  Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with Tookad , 2010, PloS one.